BioXcel Therapeutics reports executive transition

BioXcel Therapeutics, Inc., a pharmaceutical company based in New Haven, CT, has announced the departure of its Senior Vice President and Chief Commercial Officer, Matthew Wiley. The company disclosed in a recent SEC filing that Wiley's employment ceased as of Wednesday last week and he has since transitioned to a consulting role.

According to the 8-K filing, Wiley and BioXcel Therapeutics agreed to his separation from the company effective October 2, 2024. Following his departure, Wiley entered into a Separation Agreement with the company on October 3, 2024, which entitles him to severance benefits. These benefits include a pro-rated 2024 bonus, nine months of base salary continuation, and coverage of COBRA premium payments for the same duration.

Furthermore, on Monday, BioXcel Therapeutics entered into a Consulting Agreement with Commercial Science, LLC, managed by Wiley. Under this agreement, Wiley will provide consulting services to the company until December 31, 2024, at an hourly rate of $330, in addition to out-of-pocket expenses. The agreement is set to expire at the end of the year unless terminated earlier as per the terms.

BioXcel Therapeutics is known for its work in the pharmaceutical preparations industry and is traded on The Nasdaq Capital Market under the ticker symbol NASDAQ:BTAI. The company has not disclosed the reasons for Wiley's departure or details regarding the search for his successor. This news follows the standard executive transition processes and is based on the company's statements in the SEC filing.

In other recent news, BioXcel Therapeutics has made significant strides in its operations and clinical trials. The company reported Q2 revenue of $1.1 million, primarily from sales of IGALMI, surpassing expectations. BioXcel has also initiated crucial Phase 3 trials named SERENITY At-Home and TRANQUILITY In-Care, aimed at evaluating the safety and efficacy of BXCL501 for patients with bipolar disorders, schizophrenia, and Alzheimer's disease.

The company has announced a strategic workforce reduction of 28%, affecting 15 employees, to prioritize the development of BXCL501. In addition, BioXcel Therapeutics has faced challenges with Nasdaq's listing requirements and is currently evaluating options to address these deficiencies.

On the analyst front, H.C. Wainwright and Canaccord Genuity have maintained their Buy ratings on BioXcel Therapeutics, while Mizuho Securities holds a neutral stance due to concerns about the company's financial health.

InvestingPro Insights

BioXcel Therapeutics' recent executive change comes amid challenging financial circumstances for the company. According to InvestingPro data, BTAI's market capitalization stands at a modest $22.12 million, with the stock trading near its 52-week low. The company's financial health appears precarious, with InvestingPro Tips indicating that BTAI is "quickly burning through cash" and "not profitable over the last twelve months."

Despite these challenges, there are some positive indicators. The company's revenue growth is substantial, with a 131.5% increase over the last twelve months as of Q2 2024. Additionally, InvestingPro Tips reveal that "analysts anticipate sales growth in the current year," and "2 analysts have revised their earnings upwards for the upcoming period."

However, investors should note that BTAI "operates with a significant debt burden" and "analysts do not anticipate the company will be profitable this year." These factors may contribute to the ongoing volatility in the stock price, which has "fallen significantly over the last year."

For a more comprehensive analysis, InvestingPro offers 13 additional tips for BTAI, providing deeper insights into the company's financial position and market performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.